about
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phaseProtein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive LeukemiasThe Role of PTEN in Myeloid MalignanciesK252a inhibits the oncogenic properties of Met, the HGF receptorRational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemiaSensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.Identification of DOK genes as lung tumor suppressors.DOK2 inhibits EGFR-mutated lung adenocarcinoma.BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.Milestones and monitoring.Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.Update on emerging treatments for chronic myeloid leukemia.Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in RhabdomyosarcomaNew alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia.Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive LeukemiasHAUSP compartmentalization in chronic myeloid leukemia.Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 ComplexIκB-α: At the crossroad between oncogenic and tumor-suppressive signals.Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis.The challenging diagnosis of pancreatic masses: not all tumors are cancers.NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia.RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.Rare Bone Marrow Biopsy Complication: A Challenging Case of Sacroiliitis and Staphilococcus Aureus Sepsis.Tumor suppressors revival in CLLTherapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.Detection and management of retroperitoneal cystic lesions: A case report and review of the literature.Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.Emergency management of major bleeding in a case of maxillofacial trauma and anticoagulation: utility of prothrombin complex concentrates in the shock room.When collateral vessels matter: asymptomatic Leriche syndrome.HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
P50
Q26749343-6724EFF4-0B0D-4B07-BD0D-C97F2DE0AE3EQ26769590-CED9C09B-138D-4A96-B6EE-7582A2534B90Q26770608-552F72FB-99B3-4DD2-8CE3-A574E237C2DEQ28214703-0476B196-968A-4865-9EDB-15ACB5E15FB0Q28302424-AF5E36DF-BC91-449D-AE3B-238E7A4259AEQ33206246-BC6F0412-ED5E-42D6-87F5-1C3A45978093Q33327492-EE034ED3-A12B-4633-8B33-EF7C158F05D2Q34207099-8A682BD8-1E6E-49EE-8A46-5177B4EC5CA7Q35047411-94D526E5-B14E-4377-A121-B3008C5E6F1CQ35364842-3EFDCBC0-6EE5-4CE8-9C0B-030D5D88F243Q35652844-287BE748-420D-4355-9D3E-E7E62755DA7CQ36739725-0F1B334B-2AF9-4A76-953A-AD8D5A7BE3BEQ38175466-4A24FBD3-90F9-481D-A177-A760CAB3EF03Q38397515-432ED939-6E91-41F2-8451-6FFA7452EF84Q38749559-E5C28610-C9E4-4391-B13F-B4A8BCBF3208Q38810768-A0526308-003A-4384-996E-E4C080711202Q38862637-B4F6C171-391C-434B-88B9-0B92E04F4E89Q38937733-27CB734F-328D-4B79-9721-1E5C246CFEFDQ38969685-B2E26F45-8C06-4B48-99B3-EB60972BB7FBQ39023815-B3DF042C-03D6-47E2-8630-C719288B6B48Q39029101-54B60549-530C-4DB3-9DC2-D1986DDAF884Q39207728-722C2CD5-510A-43CA-9298-66867725DBD5Q39264807-235D6C91-0B18-46C6-B7E8-764FF77C9986Q39677451-F6E80F9B-CA5E-4F1D-BD5D-C0AD272E7C64Q39762949-7E9B9E9A-2753-409A-B8E9-17BE4476869FQ40234154-65488E7C-4DE3-4BFB-A365-AC94BFDD1D2EQ40450173-74733EA7-B839-4208-8458-F5DE5B066B6BQ40456936-715FBDC5-2C78-43B8-B102-08E90B98CF5BQ40619441-713D02C7-303C-473E-AFDA-65DC3EDF0105Q41008451-3C31BAEC-1EF4-446F-ABBE-6AF68F39D555Q41056246-7147E441-9912-4D67-A8FC-A5AEB1EE0387Q41143594-DE974BCD-985F-4D9E-A05D-30E87A38F647Q41547633-516C8C81-7502-4938-8597-78B1F907B9CAQ41813901-93B37008-8A40-480D-A5AF-B260998C7851Q42674490-5F4BFCD5-7406-4503-A902-EC5433FC2CAFQ43180048-CB09E800-A821-4021-A6A3-3E6340BD6E8BQ44944533-45A9F895-AAB2-45D5-ACF3-E62C596F6B95Q46491763-A7627978-C25A-47C8-AD66-86B1E26E248DQ46700803-2B42704B-D507-4D58-BDEB-89B3B31AB6EFQ46917660-3DADDE30-CFF1-4A90-922A-104514F766FA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandro Morotti
@ast
Alessandro Morotti
@en
Alessandro Morotti
@es
Alessandro Morotti
@nl
Alessandro Morotti
@sl
type
label
Alessandro Morotti
@ast
Alessandro Morotti
@en
Alessandro Morotti
@es
Alessandro Morotti
@nl
Alessandro Morotti
@sl
prefLabel
Alessandro Morotti
@ast
Alessandro Morotti
@en
Alessandro Morotti
@es
Alessandro Morotti
@nl
Alessandro Morotti
@sl
P106
P21
P31
P496
0000-0002-8407-2903